



Contact: Julie Bryant  
VP Business Development and Marketing  
GeneGo, Inc.  
(858) 756 7996  
julie@genego.com

### **NATIONAL CANCER INSTITUTE LICENSES METACORE SITE WIDE FROM GENEGO**

**St. Joseph, Michigan, May 31st, 2005** – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the National Cancer Institute has licensed MetaCore 2.5™, GeneGo’s platform for mining of high-throughput experimental data in the context of biological networks, pathways and diseases. All NCI researchers will now have access to MetaCore in house through their web browser and will be able to analyze multiple types of small to “genome scale” experimental datasets from their workstations. Based on the largest curated database of mammalian biology and physical protein interactions, the latest version, MetaCore 2.5 was released in May 2005. Among other features, it offers multiple network building algorithms and filters; maps with established metabolic and signaling pathways; advanced network comparison option; statistical cross-referencing and scoring between networks, pathways and functional processes; custom pathway editor.

“We welcome NCI as a new customer”, said Julie Bryant VP of Business Development. “Cancer datasets are inherently complex for interpretation because multiple pathways and cell types are affected. Therefore, the requirements for data mining techniques and tools in oncology are high. We are very pleased that NCI scientists chose MetaCore as an enterprise, institution-wide system”.

#### About GeneGo

GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 2.5™, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore™. For more information, please visit the company's web site at [www.genego.com](http://www.genego.com).

MetaCore™, MetaBase™ and MetaDrug™ are trademarks of GeneGo, Inc.